• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

    6/12/25 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLYB alert in real time by email

    – Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome –

    – Data Readouts Expected from Cohort 1 in 3Q 2025 and Cohort 2 in 4Q 2025 –

    Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor.

    Additionally, Rallybio announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Patients suffering from these potentially life-threatening conditions have no approved or effective therapeutic options.

    "The initiation of dosing in our confirmatory PK/PD study of RLYB116 marks a significant step forward in our mission to transform care for patients with immune PTR and refractory APS," said Stephen Uden, M.D., Chief Executive Officer of Rallybio. "These are serious, underserved hematologic conditions that demand bold innovation. With RLYB116, we are advancing a potential first-in-class therapy that represents a combined market opportunity of $5 billion. Our goal is to set a new standard of care and bring real hope to patients who have no effective treatment options. We look forward to sharing study results later this year."

    The single-blind multiple ascending dose Phase 1 confirmatory PK/PD study of RLYB116 (NCT06797375) is designed to demonstrate complete and sustained complement inhibition with favorable tolerability in healthy volunteers. The study will evaluate a 4-week treatment duration that will include two cohorts of eight participants each, randomized 3 to 1 to receive either RLYB116 or placebo once weekly. Cohort 1 will evaluate dosing of 150 mg and Cohort 2 will evaluate dosing of up to 300 mg. The study includes a 10-week follow-up period after the conclusion of treatment.

    About Platelet Transfusion Refractoriness

    PTR is a clinical condition in which patients fail to achieve the expected rise in platelet count following two or more consecutive transfusions. PTR is an urgent clinical event that increases bleeding risks and can complicate the management of conditions including bone marrow failure, hematologic malignancies, and chemotherapy treatment. The cause of PTR may be either immune or non-immune, with an immune response implicated in up to 40% of cases1. In patients with immune PTR, antibodies against platelet antigens, most commonly HLA antigens, bind to transfused platelets and target them for clearance. Evidence suggests that the complement pathway can play an important role in the clearance of platelets in patients with immune PTR. Patients who have received multiple platelet transfusions, commonly as a result of a hematologic malignancy, chemotherapy treatment, and/or transplant, are at highest risk of developing immune PTR.

    About Antiphospholipid Syndrome

    APS is a rare autoimmune disease characterized by recurrent vascular thrombosis (arterial and/or venous) and/or pregnancy-related complications (such as fetal loss), in the presence of persistent antiphospholipid antibodies. APS can be classified as primary APS or secondary APS. Primary APS occurs without any other underlying autoimmune disease, while secondary APS arises in association with other autoimmune diseases, such as systemic lupus erythematosus. The disease is driven by the production of pathogenic antiphospholipid (aPL) antibodies, including lupus anticoagulant (LA), anticardiolipin (aCL) antibodies, and anti-β2 glycoprotein-I (aβ2GPI) antibodies. These antibodies promote thrombosis and can lead to serious complications, such as stroke, ischemic attacks, deep vein thrombosis, and pulmonary embolism. Increasing evidence implicates complement system overactivation as a key contributor to both the pathogenesis and clinical manifestations of APS2-4. It is estimated that approximately 10% of patients with APS are refractory and continue to experience thromboses despite anticoagulant treatment.

    About Rallybio

    Rallybio (NASDAQ:RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation, hematology, and metabolic disorders. The Company's lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation. Rallybio also has two programs in preclinical development, including REV102, an ENPP1 inhibitor for the treatment of patients with hypophosphatasia (HPP), and RLYB332, a long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on our management's beliefs and assumptions and currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the potential of RLYB116 to address a broad range of complement-mediated diseases, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome, the expected timing of data readouts from the RLYB116 confirmatory PK/PD study, whether RLYB116 will be an effective treatment option for immune PTR and APS, whether the PK/PD confirmatory study will demonstrate improved tolerability and sustained inhibition of terminal complement, and the potential commercial opportunity for RLYB116 for the treatment of immune PTR and APS. The forward-looking statements in this press release are only predictions and are based largely on management's current expectations and projections about future events and financial trends that management believes may affect Rallybio's business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully conduct the RLYB116 PK/PD confirmatory study, and complete such study and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio's filings with the U.S. Securities and Exchange Commission (SEC), including the Quarterly Report on Form 10-Q for the period ended March 31, 2025, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

    1. Agarwal, N., Chatterjee, K., Sen, A., Kumar, P. Prevalence of platelet reactive antibodies in patient's refractory to platelet transfusions. Asian J Transfus Sci. 2014 Jul-Dec;8(2):126–127.
    2. Chaturvedi, S., Brodsky, R.A., McCrae, K.R. Complement in the Pathophysiology of the Antiphospholipid Syndrome. Front. Immunol. 2019 Mar;10:449.
    3. Chaturvedi, S., Braunstein, E.M., Yuan, X., et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239-251.
    4. Chaturvedi, S., Braunstein, E.M., Brodsky, R.A. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost. 2021 Mar;19(3):607-616.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250611385304/en/

    Investor Contacts

    Samantha Tracy

    Rallybio Corporation

    (475) 47-RALLY (Ext. 282)

    [email protected]

    Kevin Lui

    Precision AQ

    (212) 698-8691

    [email protected]

    Media Contact

    [email protected]

    Get the next $RLYB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RLYB

    DatePrice TargetRatingAnalyst
    4/9/2025Buy → Neutral
    H.C. Wainwright
    5/15/2024Overweight → Neutral
    JP Morgan
    2/7/2024$7.00 → $1.50Buy → Hold
    Jefferies
    4/17/2023$18.00Buy
    H.C. Wainwright
    4/10/2023$17.00Outperform
    Wedbush
    12/9/2022$21.00Overweight
    JP Morgan
    2/22/2022$32.00Mkt Outperform
    JMP Securities
    8/23/2021$40.00Outperform
    Evercore ISI Group
    More analyst ratings

    $RLYB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

      Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

      7/8/25 8:00:00 AM ET
      $RLYB
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

      – Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals for up to $25 million, including an upfront equity payment of $7.5 million and near term milestones. With the upf

      7/8/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

      – Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome – – Data Readouts Expected from Cohort 1 in 3Q 2025 and Cohort 2 in 4Q 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. Additionally, Rallybio announced t

      6/12/25 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Leadership Updates

    Live Leadership Updates

    See more
    • Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023

      -- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

      6/29/23 7:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

      -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

      3/6/23 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

      Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

      1/31/23 4:05:00 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Financials

    Live finance-specific insights

    See more
    • Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

      Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

      7/8/25 8:00:00 AM ET
      $RLYB
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

      -- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

      12/20/23 8:00:00 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      11/12/24 10:34:15 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rallybio Corporation

      SC 13G - Rallybio Corp (0001739410) (Subject)

      7/30/24 9:06:36 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rallybio Corporation

      SC 13G/A - Rallybio Corp (0001739410) (Subject)

      7/30/24 12:47:55 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rallybio downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Rallybio from Buy to Neutral

      4/9/25 8:36:28 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by JP Morgan

      JP Morgan downgraded Rallybio from Overweight to Neutral

      5/15/24 7:39:44 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio downgraded by Jefferies with a new price target

      Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

      2/7/24 6:42:56 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Boudreau Helen M

      4 - Rallybio Corp (0001739410) (Issuer)

      5/15/25 5:10:09 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chung Wendy

      4 - Rallybio Corp (0001739410) (Issuer)

      5/15/25 5:09:20 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hunt Ronald

      4 - Rallybio Corp (0001739410) (Issuer)

      5/15/25 5:08:25 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RLYB
    SEC Filings

    See more
    • Rallybio Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

      8-K - Rallybio Corp (0001739410) (Filer)

      7/8/25 8:08:55 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Rallybio Corp (0001739410) (Filer)

      6/27/25 4:10:37 PM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rallybio Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Rallybio Corp (0001739410) (Filer)

      5/16/25 8:31:35 AM ET
      $RLYB
      Biotechnology: Pharmaceutical Preparations
      Health Care